Trial of Aromatase Inhibition in Lymphangioleiomyomatosis (TRAIL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with Lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the rate of decline in FEV1
| Condition | Intervention | Phase |
|---|---|---|
|
Lymphangioleiomyomatosis |
Drug: Letrozole Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Trial of Letrozole in Pulmonary Lymphangioleiomyomatosis With or Without Measurable Tumors or Lymph Nodes |
- The effect on Forced Expiratory Volume in one second [ Time Frame: twelve months ] [ Designated as safety issue: No ]
- Other measures of pulmonary function [ Time Frame: twelve months ] [ Designated as safety issue: No ]FVC, DLCO, TLC,RV, FRC, 6MWT
- Quality of life measures [ Time Frame: twelve months ] [ Designated as safety issue: No ]Quality of Life, dyspnea and fatigue, functional performance
- Serum VEGF-D [ Time Frame: twelve months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Letrozole |
Drug: Letrozole
2.5 mg daily for twelve months
Other Name: Femara
|
| Placebo Comparator: Placebo |
Drug: Placebo
sugar pill given daily for twelve months
|
Detailed Description:
Lymphangioleiomyomatosis, or LAM, is an uncommon, progressive, cystic lung disease that predominantly affects young women. Pulmonary parenchymal changes consistent with LAM are found in about one third of women with tuberous sclerosis complex (TSC), an autosomal dominant tumor suppressor syndrome. LAM also occurs in a sporadic form that is not associated with germ line mutations in TSC genes. Recent evidence that recurrent LAM after lung transplantation results from seeding of the graft from a remote source and suggests a metastatic mechanism for the disease.
Since LAM occurs almost exclusively in women, and exposure to estrogen either exogenously or during pregnancy can exacerbate LAM, estrogen suppression might be expected to prevent or delay progression of disease. In preclinical studies, estrogen induces the growth of TSC2-deficient cells and tumor cells derived from LAM patients. In a xenograft model of lymphangioleiomyomatosis presented by Dr. Yu at the 2008 LAM Research Meeting, estrogen promoted the pulmonary metastases of tuberin-deficient ELT3 cells (TSC2-deficient rat uterine leiomyoma cells) in female ovariectomized CB-17-scid mice, while the estrogen inhibitor fulvestrant completely blocked estrogen-promoted pulmonary metastases. This work was recently published.
Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis)(14). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)diben-zonitrile.
In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patients at least must have a diagnosis of pulmonary lymphangioleiomyomatosis as defined by one of the following:
- CT chest compatible with LAM and a biopsy or cytology consistent withLAM.
- CT chest consistent with LAM in the setting of tuberous sclerosis, renal angiomyolipomata, cystic abdominal lymphangiomas, or chylous effusion in the chest or abdomen , or serum VEGF-D > 800 pg/uL.
- All patients must have a post bronchodilator FEV1 ≤80% predicted or DLCO ≤70% predicted or RV≥120% predicted
All patients must be postmenopausal females as defined by one of the following:
- Prior bilateral oophorectomy or bilateral ovarian irradiation.
- If age greater than 55 years, no menstrual period for 12 months or longer.
- If age 55 years or younger, must have an estradiol level in the postmenopausal range in the absence of current use of progestational agents.
- If still premenopausal, may enter if rendered medically postmenopausal on clinical grounds with the use of gonadotropin releasing hormone (e.g. leuprolide), as long as serum estradiol, FSH, and LH are in the postmenopausal range
- Patients with osteopenia or osteoporosis must be receiving appropriate treatment for their osteoporosis or osteopenia at entry into this study.
Patients must have adequate hematologic and hepatic function as defined by the following at the time of randomization.:
- Neutrophils > 1500/mm3 and platelets > 100,000/mm3
- Bilirubin < 1.25 X upper limit of normal
- SGPT (ALT) and SGOT (AST) < 2.5 X upper limit of normal
Exclusion Criteria:
- Known allergy to letrozole
- Inability to comply with pulmonary function tests or follow up visits.
- Treatment with investigational agents within 30 days
- Hormonal therapy (e.g. estrogen, progestin, LHRH agonists or antagonists, estrogen receptor blockers, estrogen receptor down regulators, aromatase inhibitors) within 30 days month of registration
- Medical or psychiatric conditions that would interfere with the ability to provide informed consent.
Contacts and Locations| Contact: Francis X McCormack, MD | 513-558-4831 | frank.mccormack@uc.edu |
| Contact: Tammy Roads, CRC | 513-558-2148 | tammy.roads@uc.edu |
| United States, Ohio | |
| University of Cincinnati | Recruiting |
| Cincinnati, Ohio, United States, 45267 | |
| Contact: Deborah M Conradi, RN 513-558-0027 deborah.conradi@uc.edu | |
| Contact: Tammy Roads, CRC 513-558-2148 tammy.roads@uc.edu | |
| Principal Investigator: Francis X McCormack, MD | |
| Sub-Investigator: Lisa R Young, MD | |
| Principal Investigator: | Francis X McCormack, MD | University of Cincinnati |
More Information
No publications provided
| Responsible Party: | Francis X. McCormack, MD, University of Cincinnati College of Medicine |
| ClinicalTrials.gov Identifier: | NCT01353209 History of Changes |
| Other Study ID Numbers: | 5708 |
| Study First Received: | May 11, 2011 |
| Last Updated: | June 10, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Lymphangioleiomyomatosis Lymphangiomyoma Lymphatic Vessel Tumors Neoplasms by Histologic Type Neoplasms Perivascular Epithelioid Cell Neoplasms Neoplasms, Connective and Soft Tissue Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Letrozole Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Aromatase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013